SLE

• Systemic lupus erythematosus (SLE) is an inflammatory autoimmune connective tissue disorder
• More common in:

  • Women
  • Asian, African, Caribbean and Hispanic ethnicity
  • Young to middle-aged adults
• SLE typically takes a relapsing-remitting course
• Cardiovascular disease and infection are significant complications
• SLE is characterised by anti-nuclear antibodies (ANA)
• SLE presents with many non-specific symptoms:

  • Fatigue
  • Weight loss
  • Arthralgia (joint pain) 
  • Non-erosive arthritis
  • Myalgia (muscle pain)
  • Fever
  • Photosensitive malar rash
  • Lymphadenopathy
  • Splenomegaly
  • Shortness of breath 
  • Pleuritic chest pain
  • Mouth ulcers
  • Hair loss
  • Raynaud’s phenomenon
  • Oedema (due to nephritis)
• The typical malar rash is “butterfly” shaped across the nose and cheeks. It is triggered or worsened by sunlight.
• Abnormal investigation results in SLE:

  • Autoantibodies
  • FBC - anaemia of chronic disease, low WCC and low platelets
  • CRP and ESR may be raised
  • C3 and C4 may be decreased in active disease
  • Urinalysis and urine protein:creatinine ratio shows proteinuria in lupus nephritis
  • Renal biopsy may be used to investigate for lupus nephritis
• Autoantibodies:

  • 85% will be positive for ANA (non specific to SLE)
  • Anti-dsDNA are highly specific to SLE - good to monitor disease activity
• An extractable nuclear antigen panel looks for antibodies to specific proteins in the cell nucleus and helps diagnose and distinguish between specific connective tissue disorders:

  • Anti-Smith (highly specific to SLE but not very sensitive)
  • Anti-centromere antibodies (most associated with limited cutaneous systemic sclerosis)
  • Anti-Ro and anti-La (most associated with Sjögren’s syndrome)
  • Anti-Scl-70 (most associated with systemic sclerosis)
  • Anti-Jo-1 (most associated with dermatomyositis)
• Antiphospholipid antibodies and antiphospholipid syndrome can occur secondary to SLE in up to 40% of patients. These antibodies are associated with an increased risk of venous thromboembolism. 
• Diagnostic criteria:

  • European league against rheumatism (EULAR) criteria
  • American college of rheumatology (ACR) criteria
  • Takes into account the clinical features and autoantibodies suggestive of SLE
• Cardiovascular disease is a leading cause of death. Chronic inflammation in blood vessels leads to hypertension and coronary artery disease.
• Infection is more common, both from the disease process and secondary to immunosuppressant drugs.
• Anaemia in SLE can be due to anaemia of chronic disease, autoimmune haemolytic anaemia, bone marrow suppression by medications or kidney disease. It can also cause leucopenia (low white cells), neutropenia (low neutrophils) and thrombocytopenia (low platelets).
• Pericarditis is a complication of SLE(inflammation of the pericardial sac surrounding the heart) causes sharp chest pain that gets worse on lying flat.
• Pleuritis is a complication of SLE -  (inflammation of the lining of the lungs) causes sharp chest pain on inspiration.
• Interstitial lung disease is a complication of SLE - can be caused by inflammation in the lung tissue, leading to pulmonary fibrosis.
• Lupus nephritis (inflammation in the kidney) can progress to end-stage renal failure. Investigations include a urine protein:creatinine ratio and renal biopsy. The renal biopsy is often repeated to assess the response to treatment.
• Neuropsychiatric SLE is caused by inflammation in the central nervous system. It can present with optic neuritis (inflammation of the optic nerve), transverse myelitis (inflammation of the spinal cord) or psychosis.
• Recurrent miscarriage is more common in SLE. There is also an increased risk of intrauterine growth restriction, pre-eclampsia and pre-term labour.
• Venous thromboembolism may be associated with antiphospholipid syndrome occurring secondary to SLE. 
• Management first line -options:

  • Hydroxychloroquine 
  • NSAIDs
  • Steroids (e.g., prednisolone)
• Treatment options for resistant or more severe SLE include:

  • DMARDs (e.g., methotrexate, mycophenolate mofetil or cyclophosphamide)
  • Biologic therapies 
• Biological therapies include:

  • Rituximab (a monoclonal antibody that targets the CD20 protein on the surface of B cells)
  • Belimumab (a monoclonal antibody that targets B-cell activating factor)
• Suncream and sun avoidance are essential measures in managing the photosensitive malar rash.